Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iniparib + gemcitabine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Iniparib (BSI-201, also known as SAR240550) is a novel investigational anti-cancer agent that was initially thought to act as a poly(ADP-ribose) polymerase (PARP) inhibitor. However, subsequent studies have shown that it does not possess characteristics typical of the PARP inhibitor class. Its exact mechanism of action remains unclear but is believed to involve induction of DNA damage (as indicated by gamma-H2AX), cell cycle arrest at the G2/M phase, and potentiation of the effects of DNA-damaging agents in tumor cells. Iniparib has been studied primarily in combination with chemotherapeutic agents such as gemcitabine and carboplatin for various cancers including triple-negative breast cancer and ovarian cancer[1][4][5][8]. Gemcitabine is a nucleoside analog used as chemotherapy.
- Other names
- iniparib + gemcitabine
02
Targets
DNA polymerase familyPARP1 (Poly (adp-ribose) polymerase 1)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on iniparib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iniparib + gemcitabine.